A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
Completed
Alza Corporation, DE, USA
Phase 3
1996-07-01
The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that
of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed
urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the
treatment of the symptoms of overactive bladder.
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
Completed
Alza Corporation, DE, USA
Phase 3
1969-12-31
The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride)
Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in
the reduction of urge urinary incontinence episodes during a 12-week treatment period in
patients with overactive bladder. The secondary objective is to compare the tolerability of
DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week
treatment period.
An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
Completed
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
2004-05-01
The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended
release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract
symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from
baseline to Week 12 or the Final Visit.
Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-12-01
The objective of this study was to investigate the single-dose relative bioavailability of
Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following
an oral, single 20 mg (4 x 5 mg) dose under fed conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
